aladotril (Fasidotril)

inhibits neutral endopeptidase; prodrug of aladotrilat
Also Known As:
Fasidotril; BP 1137
Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results


1. Ozdemir, Vural: 1 article (09/2003)
2. Ozdener, Fatih: 1 article (09/2003)
3. Laurent, S: 1 article (05/2000)
4. Gros, C: 1 article (05/2000)
5. Marie, C: 1 article (05/2000)
6. Schwartz, J C: 1 article (05/2000)
7. Lecomte, J M: 1 article (05/2000)
8. Bralet, J: 1 article (05/2000)
9. Boutouyrie, P: 1 article (05/2000)
10. Azizi, M: 1 article (05/2000)

Related Diseases

1. Hypertension (High Blood Pressure)
09/01/2003 - "Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe."
05/01/2000 - "After a 4-week placebo run-in period, 57 patients with essential hypertension were included in a randomized double-blind, placebo-controlled, parallel-group study and received orally either fasidotril (100 mg twice daily) or placebo for 6 weeks. "
09/01/2003 - "Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). "
05/01/2000 - "After 42 days, compared with placebo, fasidotril lowered supine systolic and diastolic blood pressures by 7.4/5.4 mm Hg and standing blood pressure by 7.6/6.8 mm Hg. Fasidotril, a dual NEP/ACE inhibitor, was an effective oral antihypertensive agent during chronic treatment in high-renin renovascular rats, normal-renin SHR, and low-renin DOCA-salt hypertensive rats and in patients with essential hypertension."
05/01/2000 - "The aim of this study was to assess the antihypertensive activity of fasidotril, a dual inhibitor of neprilysin (NEP) and angiotensin I-converting enzyme (ACE), in various models of hypertension in rats (spontaneously hypertensive rats [SHR]; renovascular Goldblatt 2-kidney, 1-clip rats; and deoxycorticosterone acetate [DOCA]-salt hypertensive rats) and in patients with mild-to-moderate essential hypertension. "
2. Myocardial Infarction
3. Heart Failure
4. Cardiomegaly (Heart Hypertrophy)

Related Drugs and Biologics

1. Neprilysin (Neutral Endopeptidase)
2. Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3. aladotrilat
4. Desoxycorticosterone (DOCA)
5. Renin
6. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)

Related Therapies and Procedures

1. Surgical Instruments (Clip)